November 14, 2012 11:54 AM Eastern Daylight Time

BUSINESS WIRE

Forxiga™ (dapagliflozin), First-In-Class SGLT2 That Works Independently of Insulin, Now Approved in European Union for Treatment of Type 2 Diabetes

Dapagliflozin Clinical Trial Fact Sheet

Dapagliflozin Clinical Trial Fact Sheet

Download

Adobe PDF 134.2 KB

Smart Multimedia Gallery

Professor Clifford J Bailey Professor of Clinical Science, Life and Health Sciences University of Aston, UK

Professor Clifford J Bailey Professor of Clinical Science, Life and Health Sciences University of Aston, UK

Play and Share Video

http://www.businesswire.com/multimedia/home/20121114006517/en/2783591/Forxiga%E2%84%A2-dapagliflozin-First-In-Class-SGLT2-Works-Independently-Insulin

View and Share Logo

Download Small

Dapagliflozin Clinical Trial Fact Sheet

Dapagliflozin Clinical Trial Fact Sheet

Type 2 Diabetes Media Fact Sheet

Type 2 Diabetes Media Fact Sheet

View and Share Document

Download Adobe PDF

Dapagliflozin Medical Media Fact Sheet

Dapagliflozin Medical Media Fact Sheet

View and Share Document

Download Adobe PDF

Kidney Fact Sheet

Kidney Fact Sheet

View and Share Document

Download Adobe PDF

Share

Email

All News | News with Multimedia > Press Release: Forxiga™ (dapagliflozin), First-In-Class SGLT2 ...